{"id":"W4389220803","doi":"10.1182/blood-2023-174510","title":"3-Year Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) As First-Line Therapy in Patients with High-Risk Large B-Cell Lymphoma (LBCL)","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Internal medicine; Fludarabine; Chemotherapy regimen; Phases of clinical research; International Prognostic Index; Regimen; Diffuse large B-cell lymphoma; Interim analysis; Surgery; Oncology; Lymphoma; Cyclophosphamide; Chemotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006940915,0.0002840622,0.001030206,0.001297595,0.00006652448,0.00001249755,0.0002770304,0.0001200402,0.001158571],"category_scores_gemma":[0.00008807436,0.0002248201,0.0002266972,0.003597209,0.00007526853,0.00005656755,0.0001106943,0.0002012236,0.00003167277],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00006154928,"about_ca_system_score_gemma":0.0001425579,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001636114,"about_ca_topic_score_gemma":0.0007994657,"domain_scores_codex":[0.9968692,0.0002035361,0.0006711458,0.0005424239,0.001201031,0.0005126734],"domain_scores_gemma":[0.9980304,0.0001890372,0.0002921257,0.0009948979,0.0003133602,0.000180238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.007158828,0.103623,0.8682532,0.00008746384,0.004302098,0.0001462908,0.002886716,0.00008027854,0.007063278,0.000004461615,0.00005935601,0.006335007],"study_design_scores_gemma":[0.2404877,0.02370444,0.6983905,0.00006251624,0.002117923,9.75832e-7,0.0009916833,0.0003251329,0.03336781,0.0000129385,0.0002692268,0.0002692119],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.997653,0.000140997,0.000005126361,0.0000380617,0.00003270683,0.001449172,0.0002068774,0.00005936985,0.0004147011],"genre_scores_gemma":[0.9978167,0.0005479071,0.00004809808,0.00003313863,0.00004683184,0.00008051739,0.0002410434,0.00006825123,0.001117506],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2333289,"threshold_uncertainty_score":0.9997545,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01785151884795993,"score_gpt":0.2935026324855429,"score_spread":0.275651113637583,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}